1. ZBTB18 inhibits SREBP-dependent lipid synthesis by halting CTBPs and LSD1 activity in glioblastoma
- Author
-
Roberto Ferrarese, Annalisa Izzo, Geoffroy Andrieux, Simon Lagies, Johanna Paulina Bartmuss, Anie Priscilla Masilamani, Alix Wasilenko, Daniela Osti, Stefania Faletti, Rana Schulzki, Shuai Yuan, Eva Kling, Valentino Ribecco, Dieter Henrik Heiland, Stefan Tholen, Marco Prinz, Giuliana Pelicci, Bernd Kammerer, Melanie Boerries, and Maria Stella Carro
- Subjects
Histone Demethylases ,Ecology ,Health, Toxicology and Mutagenesis ,Fatty Acids ,Humans ,Plant Science ,Glioblastoma ,Sterol Regulatory Element Binding Protein 1 ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Lipids - Abstract
Enhanced fatty acid synthesis is a hallmark of tumors, including glioblastoma. SREBF1/2 regulate the expression of enzymes involved in fatty acid and cholesterol synthesis. Yet, little is known about the precise mechanism regulating SREBP gene expression in glioblastoma. Here, we show that a novel interaction between the co-activator/co-repressor CTBP and the tumor suppressor ZBTB18 regulates the expression of SREBP genes. In line with our findings, metabolic assays and glucose tracing analysis confirm the reduction in several phospholipid species upon ZBTB18 expression. Our study identifies CTBP1/2 and LSD1 as co-activators of SREBP genes and indicates that the functional activity of the CTBP-LSD1 complex is altered by ZBTB18. ZBTB18 binding to the SREBP gene promoters is associated with reduced LSD1 demethylase activity of H3K4me2 and H3K9me2 marks. Concomitantly, the interaction between LSD1, CTBP, and ZNF217 is increased, suggesting that ZBTB18 promotes LSD1 scaffolding function. Our results outline a new epigenetic mechanism enrolled by ZBTB18 and its co-factors to regulate fatty acid synthesis that could be targeted to treat glioblastoma patients.
- Published
- 2022